Premium
Transporters in Drug Development: Scientific and Regulatory Considerations
Author(s) -
Zhang Lei,
Huang ShiewMei,
Reynolds Kellie,
Madabushi Rajanikanth,
Zineh Issam
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1214
Subject(s) - drug development , drug , clinical pharmacology , engineering ethics , pharmacology , medicine , engineering
Transporters can affect a drug's pharmacokinetics (PK) by controlling absorption, distribution, and elimination processes. They can also affect a drug's pharmacodynamics (PD) by influencing its access to the site of action. More recently, transporters have become important as drug targets (e.g., urate transporter inhibitors as treatment for gout and sodium/glucose cotransporter-2 inhibitors for treating type 2 diabetes). As such, it is important to consider the role of transporters during drug development.